Pharming Group NV 2015 AR2
The report highlights Pharming Group N.V.'s operational and financial performance for the fiscal year 2015. Key achievements include the expansion of the RUCONEST® franchise through new distribution agreements in Colombia, South Korea, and Venezuela, alongside a five-year data exclusivity extension granted by the US FDA. Financially, revenues from product sales increased significantly to €8.6 million, driven by a full year of sales in the US, although total revenues decreased to €10.8 million. The company also advanced its pipeline with new development projects in Pompe and Fabry's diseases and strengthened its financial position through a $17 million debt facility.
Company: Pharming Group NV
Sector: Manufacturing
Country: Netherlands
Year: 2015
Type: AR2
Pages: 132
Back to company
Pharming Group NV
Annual Report
The report highlights Pharming Group N.V.'s operational and financial performance for the fiscal year 2015. Key achievements include the expansion of the RUCONEST® franchise through new distribution agreements in Colombia, South Korea, and Venezuela, alongside a five-year data exclusivity extension granted by the US FDA. Financially, revenues from product sales increased significantly to €8.6 million, driven by a full year of sales in the US, although total revenues decreased to €10.8 million. The company also advanced its pipeline with new development projects in Pompe and Fabry's diseases and strengthened its financial position through a $17 million debt facility.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees